Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access

- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -

GlobeNewsWire • Jul 14, 2026

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Humacyte, Inc. (HUMA) closed the most recent trading day at $0.71, moving +2.31% from the previous trading session.

Zacks Investment Research • 16 hours ago

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change from its previous close.

Zacks Investment Research • Jun 30, 2026

Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.

Zacks Investment Research • Jun 25, 2026

Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • Jun 19, 2026

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous trading session.

Zacks Investment Research • Jun 16, 2026

Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript

Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript

Seeking Alpha • Jun 16, 2026

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care – – Company to hold investor event today, June 15 th , at 5:00 p.m. ET – DURHAM, N.C.

GlobeNewsWire • Jun 15, 2026

Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know

Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Jun 15, 2026

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 -

GlobeNewsWire • Jun 10, 2026